Figure 1.

ALCAT1 deficiency or inhibition by A320 protects mice from 1‐methyl‐4‐phenyl‐1,2,4,6‐tetrahydropyridine (MPTP)‐induced motor deficits. (a) Male ALCAT1^−/− mice and wild‐type (WT) controls were injected intraperitoneally (i.p.) with MPTP at 30 mg/kg or saline for 7 days, followed by behavioral tests for four consecutive days after the final injection, including: (b) travel speed (m/s) during 6 min; (c) time (sec) to traverse the beam; (d) latency (sec) to fall off the rotated rod; and (e) time (sec) to climb pole. (f) Male C57BL/6 mice were injected i.p. with A320 at 1 mg/kg or vehicle for 3 days prior to the first dose of MPTP and continued for 13 consecutive days. Behavioral tests were performed on days 4–11 after the last dose of MPTP injection, including: (g) travel speed (m/s) during 6 min; (h) time (sec) to traverse the beam; (i) latency (sec) to fall off the rotated rod; (j) time (sec) to climb pole. Data are mean ± SEM; n = 10, *p < 0.05, **p < 0.01, and ***p < 0.001